ScienceAntisense oligonucleotides or small interfering RNAs: Which make better therapeutics?
A Cell Reports Medicine review examines nucleic acid therapies—programmable drugs that act at the gene transcript level—and advances in their chemistry and delivery.
TLDR
The Cell Reports Medicine review surveys nucleic acid therapies, summarizes advances in chemistry and delivery, and discusses developments the authors expect next. A post sharing it asks how antisense oligonucleotides (ASOs) compare with small interfering RNAs (siRNAs), saying these and related molecular therapies have led to more than 20 FDA approvals.
Antisense oligonucleotides or small interfering RNAs: Which make better therapeutics?
A Cell Reports Medicine review examines nucleic acid therapies—programmable drugs that act at the gene transcript level—and advances in their chemistry and delivery.
TLDR
The Cell Reports Medicine review surveys nucleic acid therapies, summarizes advances in chemistry and delivery, and discusses developments the authors expect next. A post sharing it asks how antisense oligonucleotides (ASOs) compare with small interfering RNAs (siRNAs), saying these and related molecular therapies have led to more than 20 FDA approvals.
